Featured
mRNA Personalized Cancer Vaccine for Pancreatic Cancer Shows 90% Efficacy in Landmark Phase 3 Trial
A landmark Phase 3 trial reveals that a personalized mRNA neoantigen vaccine achieves a 90% recurrence-free survival rate in resected pancreatic cance...
Read Full Story →